© 2022 MJH Life Sciences and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
2 Clarke DriveSuite 100Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Expert oncologists Evan Y. Yu, MD; Andrew J. Armstrong, MD, MSc; Pedro C. Barata, MD, MSc; Tanya B. Dorff, MD; and Mary-Ellen Taplin, MD, review data from ASCO 2022 and discuss updates on the management of prostate cancer.
June 28th 2022
Centering discussion on a clinical scenario of metastatic hormone-sensitive prostate cancer, expert panelists consider how they might approach frontline therapy in this setting.
A brief review of the respective roles of multidisciplinary care and genetic testing in patients diagnosed with metastatic hormone-sensitive prostate cancer.
July 5th 2022
Expert perspectives on frontline AR-targeted therapy in metastatic hormone-sensitive prostate cancer, with deference to recent clinical trial data on triplet therapy.
Continuing their discussion on frontline AR-targeted therapy in mHSPC, experts define how accessibility and patient eligibility impact treatment selection.
July 12th 2022
Expert panelists briefly share their excitement for trial data readouts in metastatic hormone-sensitive prostate cancer from the annual ASCO 2022 Annual meeting.
Closing out their discussion on a clinical scenario of metastatic HSPC, expert panelists consider optimal patient monitoring strategies and novel imaging.
July 19th 2022
Shared insight on a clinical scenario of a patient with nonmetastatic castration-resistant prostate cancer who was treated with prostatectomy and adjuvant therapy.
Expert perspectives on monitoring patients with nonmetastatic castration-resistant prostate cancer and deciding when to initiate systemic therapy.
July 26th 2022
A comprehensive discussion on factors that inform treatment selection of available AR-targeted therapy for patients with nonmetastatic CRPC.
Before closing out their second module, panelists highlight remaining unmet needs in the setting of nonmetastatic castration-resistant prostate cancer.
August 2nd 2022
Shared insight on a clinical scenario of metastatic castration-resistant prostate cancer managed with androgen-deprivation therapy and docetaxel.
Expert oncologists define appropriate imaging strategies, conventional and novel, in patients with metastatic castration-resistant prostate cancer.
August 9th 2022
A comprehensive review of available agents in the setting of metastatic CRPC, with discussion of optimal sequencing in later lines of therapy.
Panelists share caution toward use of mTOR-, PI3K-, and AKT-targeted therapies in the setting of PTEN loss in metastatic CRPC.
August 16th 2022
Focusing on the advent of PARP inhibitors in metastatic castration-resistant prostate cancer, genitourinary cancer specialists provide an overview of clinical trials and agents in this setting.
Expert perspectives on how PARP inhibition will fit into the real-world management of patients with metastatic castration-resistant prostate cancer.